“Kevyt” diluutio 
" Coala-Life Group intends to carry out a rights issue of units, guaranteed to 75 percent, consisting of new shares and warrants of approximately SEK 101 million
The Rights Issue comprise no more than 198,704,085 units and each unit consist of one (1) new share and one (1) warrant issued free of charge. The subscription price is SEK 0.51 per unit and refers to the share. "
Osakemäärä ennen antia 79,4m.
"The main reason for the Rights Issue is to finance the Company’s continued commercial expansion, primarily in the United States. QorumPartners, which is a service company in Managed Remote Patient Monitoring, was established in the beginning of 2022 and has since grown rapidly. In August 2022, Coala Life acquired Vitrics, which also is service company within the Managed Remote Patient Monitoring space. Sales of the medical device Coala Heart Monitor has developed well, with an increasing number of recurring customers and in Sweden the sales organization has been reorganized to create a better offering for the Swedish healthcare system. In the spring of 2022, the Coala Heart Monitor received 510K approval for use in lung auscultation. Coala Life’s patient platform and software has been further developed and multiple milestones related to this have been reached.
To ensure that the Company has the best conditions to build and grow its business, primarily in the United States, and to develop its product offering and establish sustainable profitability, the board of directors intends to convene an extraordinary general meeting to resolve on the Rights Issue (as well as the Overallotment Option and the Commitment Consideration Issue). Upon full subscription, the Company will initially receive proceeds of approximately SEK 101 million before deduction of transaction costs. Should the Overallotment option be fully exercised, the Company will initially receive additional proceeds amounting to approximately SEK 10.1 million before deduction of transaction costs. Approximately SEK 25 million is expected to be contributed to the Company through set-off of debt. The transaction costs related to the various issues are estimated to amount to approximately SEK 10.9 million. The Company may furthermore receive additional proceeds in the event that the warrants are exercised for the subscription of new shares during the third quarter of 2023.
The expected net proceeds will, following below order of priority and with the approximate split specified in parentheses, be used for;
-
Continued market penetration in the United States (50%)
-
R&D (12.5%)
-
Financing of day-to-day operations (37.5%)"
Jonkinlainen anti oli odotettavissa, kun yhtiö panostaa kasvuun, mutta turskaa tulee ainakin alkuvaiheessa runsaasti. Tämä annin koko kuitenkin aika huima, varsinkin kun siitä suurin osa jo ennalta merkitty . No parempi tämäkin kuin konkurssi, kun yhtiön tuotteet kuitenkin vaikuttaa pätevältä ja liiketoiminnallisestikin lupaavalta, kunhan alun tappiollisuudesta selvitään